Effects of Metronomic Irinotecan on Colon Cancer
Author Information
Author(s): G. Bocci, A. Falcone, A. Fioravanti, P. Orlandi, A. Di Paolo, G. Fanelli, P. Viacava, A. G. Naccarato, R. S. Kerbel, R. Danesi, M. Del Tacca, G. Allegrini
Primary Institution: University of Pisa, Pisa, Italy
Hypothesis
Can metronomic irinotecan chemotherapy effectively inhibit tumor growth and angiogenesis in preclinical models of colon cancer?
Conclusion
Metronomic irinotecan significantly inhibits tumor growth and reduces microvessel density without causing toxicity.
Supporting Evidence
- Metronomic CPT-11 significantly inhibits HT-29 tumor growth in the absence of toxicity.
- Combination treatment with semaxinib enhances the antitumor effects of metronomic irinotecan.
- Metronomic chemotherapy reduces microvessel density in tumor tissues.
Takeaway
This study shows that giving a little bit of medicine often can help fight cancer without making the mice sick.
Methodology
The study used in vitro and in vivo experiments to assess the effects of metronomic irinotecan and its combination with semaxinib on tumor growth and angiogenesis.
Potential Biases
Potential biases may arise from the use of animal models and the specific conditions of the experiments.
Limitations
The study was conducted in preclinical models, which may not fully replicate human responses.
Participant Demographics
CD nu/nu male mice were used for in vivo studies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website